In this interview we discuss the latest treatments and research for gastrointestinal cancers with Dr. Cathy Eng, associate professor, department of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center.
In this interview we discuss the latest chronic myeloid leukemia treatment and research with Dr. Michael Deininger, chief of the division of hematology at the University of Utah School of Medicine.
Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH.
To kick off SABCS 2012, we discuss the use of molecular testing for the diagnosis and treatment of breast cancer patients in the clinical setting with Dr. Antonio Wolff of the Kimmel Cancer Center at Johns Hopkins University, one of the presenter's during the "Practical Use of Molecular Profiling" session at this year's symposium.
In this podcast we discuss the recent advances in the management and treatment of metastatic melanoma with Jeffrey Sosman, MD, medical oncologist and director of the Melanoma and Tumor Immunotherapy Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
In this podcast we discuss integrating palliative care into standard oncology care with Thomas J. Smith, director of palliative medicine at Sidney Kimmel Comprehensive Cancer Center.
In this podcast we discuss the long-term effects of chemotherapy on the cognitive function of cancer patients and the current status of research in this field.
We speak with Clifford Hudis, MD, Memorial Sloan-Kettering Cancer Center, about the recent advances in breast cancer treatment and the top news to come out of this year’s ASCO Breast Cancer Symposium.
The cost of cancer treatment has at least doubled since 1987 and there does not appear to be any hint that cancer care costs will decline. In this podcast we discuss the reasons for the increase in costs, as well as the ethics of cancer care cost containment.
Chemotherapy regimens that 10 years ago cost $30,000 have now increased ten-fold. Could a new research facility help make cancer care affordable again?